Arbutamine stress echocardiography

Noninvasive diagnosis of coronary artery disease in women

Cardiovascular disease is the leading cause of mortality and significant morbidly among women in the United States. The frequent absence of antecedent symptoms, the potential for an initial fatal cardiac event and the limitations of currently available noninvasive diagnostic tests pose challenges to healthcare practitioners as they try to optimally risk stratify patients. Therefore, the purpose of this article is to discuss the accuracy of noninvasive tests for CAD diagnosis in women.

Comparing stress testing methods. Available techniques and their use in CAD evaluation

Exercise stress testing remains one of the most widely used techniques in assessing functional capacity and in confirming a diagnosis of CAD. Its sensitivity and specificity are approximately 63% and 74%, respectively. The technique is safe when administered and supervised by qualified personnel who are trained to recognize contraindications and other reasons for termination of the test. More recently, echocardiography has been combined with exercise stress testing. It is a well-tolerated and valuable procedure for noninvasive evaluation of CAD. The sensitivity and specificity of stress echocardiography are higher than those of exercise stress testing and comparable to those of nuclear perfusion imaging. Continuing improvements in digital image analysis, cost, and the availability of contrast agents promise to make noninvasive stress testing even more useful in the years to come. Newer contrast and concomitant perfusion agents are on the horizon and may prove to be a reality in the echocardiographic laboratories of the future.

Pharmacological stress agents for evaluation of ischemic heart disease

Ischemic heart disease is the leading cause of death in the developed countries for those older than 65 years of age. In patients suspected to have coronary artery disease a stress test should be performed to identify the vulnerability of the myocardium to ischemia. As a rule of thumb, the evaluation of coronary artery disease is best done by exercise stress test. In patients who are not able to exercise adequately, pharmacological stress agents are used. The commonly used agents are the coronary vasodilators, adenosine and dipyridamole and the catecholamines, dobutamine and arbutamine. These agents are combined with imaging techniques to increase the sensitivity and specificity of the test. These agents have been widely used and have an excellent safety profile. Another advantage in using pharmacological stress agents is that they do not affect the image quality, especially with echocardiography and magnetic resonance imaging. Ongoing developments hold promise for safer and more reliable pharmacological stress agents in the future.

Diagnostic and prognostic use of stress echocardiography in stable patients

Stress echocardiography is an effective diagnostic and prognostic technique in stable patients with known or suspected coronary artery disease (CAD), myocardial infarction, or chronic left ventricular dysfunction and those undergoing noncardiac surgery. Stress echocardiography is sensitive and specific for the detection and extent of CAD. Negative tests confer a high negative predictive value for cardiac events regardless of the clinical risk. Positive studies confer a high positive predictive value for ischemic events in patients with intermediate to high clinical risk. Stress echocardiography provides incremental prognostic information relative to clinical, resting echocardiographic, and angiographic data. Meta-analysis studies have shown that the diagnostic and prognostic information provided by stress echocardiography is comparable to that from radionuclide scintigraphic stress tests. Stress echocardiography may be more specific for the detection and extent of CAD, whereas radionuclide scintigraphy may be more sensitive for one-vessel disease. Sensitivities are similar for the detection and extent of disease in patients with multivessel CAD.

Diagnostic and Prognostic Use of Stress Echocardiography and Radionuclide Scintigraphy

Stress echocardiography and radionuclide scintigraphy are effective diagnostic and prognostic techniques in patients with known or suspected coronary artery disease (CAD), myocardial infarction (MI), chronic left ventricular dysfunction (LVD), and those undergoing noncardiac surgery. Both are sensitive and specific for the detection and extent of CAD. Negative tests confer a high negative predictive value for cardiac events irrespective of clinical risk. Positive studies confer a high positive predictive value for ischemic events in patients with intermediate to high clinical risk. Both provide incremental diagnostic and prognostic information relative to clinical, resting echocardiographic, and angiographic data. Meta-analysis studies have shown that the diagnostic and prognostic information provided by stress echocardiography is comparable with radionuclide scintigraphic stress tests. Stress echocardiography may be more specific for the detection and extent of CAD, whereas radionuclide scintigraphy may be more sensitive for single-vessel disease. Sensitivities are similar for the detection and extent of disease in patients with multivessel CAD.

Stress Echocardiography: A Review of the Principles and Practice

Stress echocardiography, both pharmacologic and physiological, is an established noninvasive diagnostic method of detecting coronary artery disease. It also has a role in the assessment of patients with chest pain, the assessment of cardiovascular risk before noncardiac surgery, the assessment of patients after a myocardial infarction, the detection of viability in dysfunctional myocardium, and the prediction of functional recovery. The prognostic value of stress echocardiography is emerging. In this article, we discuss the methodology, diagnostic accuracy, and various clinical applications of stress echocardiography. We also review its limitations and compared it with other noninvasive methods of assessing patients with coronary artery disease.